SEC61 translocon subunit gamma (SEC61G)

The SEC61G divergent transcript (SEC61G-DT) is not a well-established molecule in standard scientific databases. There is no evidence that "SEC61G-DT" (SEC61G divergent transcript) is recognized as a canonical molecule or therapeutic target. All functional and therapeutic relevance described is associated with the canonical SEC61G protein, which is the gamma subunit of the SEC61 translocon complex, a key component controlling translocation and membrane integration of nascent proteins in the ER. It plays essential roles in protein processing, immune evasion (by stabilization and glycosylation of immune checkpoint molecules such as PD-L1), and tumor cell survival. Overexpression and amplification of SEC61G are associated with several cancers, notably EGFR-amplified glioblastoma. Pharmacological blockade of the SEC61 complex is under investigation as a cancer therapy. If the intent was SEC61G, it is considered a therapeutic target.

Other names

SEC61GSSS1Sec61 translocon gamma subunitSEC61 translocon subunit gamma

Inhibition of protein translocation into ER, downregulation of immune checkpoint glycosylation, suppression of antigen processing and presentation, induction of tumor cell death by disrupting ER function